7
May
2020
Randomized Controlled Trials For Healthcare Delivery Work; Now Let’s Do More At Scale
The value of randomized controlled trials (RCTs) in healthcare delivery was highlighted earlier this year with the publication in the New England Journal of Medicine (NEJM) of a paper that rigorously evaluated a deeply appealing hypothesis: that you can improve care and reduce costs by focusing on “superutilizers” – the patients who consume the most healthcare resources. I discussed this... Read More
6
May
2020
Extending an Immune Medicine Platform Against the Common Foe
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
May
2020
Giving Models and Modelers a Bad Name
As someone who has spent a career building and studying disease models, primarily for cancer, the latest update from Chris Murray and the IHME model makes me cringe. The IHME model, readers will recall, has been frequently cited by the White House coronavirus task force. On May 4, the IHME called a press conference to release the results of their... Read More
5
May
2020
The Spirit of Giving Is More Powerful Than Ever
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
May
2020
Beyond CAR-T: New Engineered Immune Cell Types Head to the Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
May
2020
If We’re Smart, COVID19 Will Strengthen Our Defense Against Drug-Resistant Bugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
May
2020
A Time for Empathy
This is a fragile moment. It’s May 1. Some of us have been in social isolation for two solid months. Everyone’s at some point on the continuum of stir crazy. More than 30 million people are out of work. Tempers are flaring. Protestors are carrying guns. It’s obvious we can’t sustain a maximalist social-distancing policy much longer. Today, we have... Read More
30
Apr
2020
Real-Time Tracking of Viral Outbreaks: Emma Hodcroft on The Long Run
Today’s guest on The Long Run is Emma Hodcroft. Emma is a molecular epidemiologist at the University of Basel, and the co-developer of Nextstrain. NextStrain is the open-source toolkit built for real-time tracking of viral outbreaks. In the early days, teams led by Trevor Bedford at Fred Hutch and Richard Neher in Basel used it to track viral evolution of... Read More
28
Apr
2020
Keeping an Academic Lab Afloat in a Pandemic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Apr
2020
We Didn’t Become the World Biotech Leader By Sealing Ourselves Off
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Apr
2020
Capturing Family History, While We Have Time
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Apr
2020
How a Simple Gesture Morphed Into a Full-Time Effort to Feed the Frontline
As a night owl, I relish the “me time” hours from midnight to 2 a.m. Snuggled in bed, the rest of my family asleep, I scroll through the news and laugh at friends’ video posts. Like many other science writers, I spent many of those quiet hours in February following the relentless spread of the new SARS-CoV-2 virus, especially as... Read More
25
Apr
2020
A San Francisco Doctor Answers the Call to New York
The week things got really interesting was the week of March 16. That’s when Sara Cody, the Santa Clara County public health officer, and her legion of public health heroes made the gutsy call – the first of its kind in the nation — to shut things down in the entire 6-county San Francisco Bay Area, home to more than... Read More
24
Apr
2020
A Sad Week of Reckless Leadership
The first US death from COVID-19 was reported on Feb. 29. Today, Apr. 24, the US death toll exceeds 50,000. That’s more than Italy and Spain combined. Even though we had early warning. It’s tragic. There’s also a reason why the death toll hasn’t been higher. It’s because of large-scale physical distancing in this expansive country of 330 million people.... Read More
22
Apr
2020
Massachusetts Biotechs Consider How to Return Safely, and Create a New Normal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Apr
2020
Build Back Better
As the nation has struggled to cope with the devastation of the COVID-19 pandemic, New York Governor Andrew Cuomo has become the voice so many have looked to for support and leadership. What Cuomo seems both to offer and effectively communicate is not just a mastery of the facts, but also a grounded yet hopeful narrative. The story he projects... Read More
21
Apr
2020
How to Navigate the Blizzard of COVID-19 Antibody Studies
What is the single thing you wish you knew about COVID-19? Here is what I wonder about most. How many of us have had it already without knowing it – either because we did not have symptoms, or because we thought it was something else, or because we thought it might be COVID-19 but we could not get tested?... Read More
21
Apr
2020
Singapore’s COVID19 Crisis: Forgetting to Check the Blind Spot
It is with a heavy heart that I pen this follow-up piece on Singapore’s COVID19 situation. In the past few months, the city state has been hailed as an exemplar of early, preemptive and targeted response to combat the pandemic. Other countries have studied its response. As I wrote here on Mar. 19, despite being a densely populated high-risk state,... Read More
20
Apr
2020
Cultivating a Tolerance for Adversity in Our Teams and Our Communities
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Apr
2020
The Real Question is How to Restart
When?? When can we finally go back to something resembling a “normal” life, go back to work and restart our economies, embrace again long-lost family, friends, co-workers? And, in too many cases, when can we get together to properly mourn those we have lost? I cannot tell you “when.” Everyone wants the answer to that question. I do, too. But... Read More